Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

Lung Cancer

Volumn 62, Issue 2, 2008, Pages 253-260

  Helbekkmo, Nina ^a   Aasebø, Ulf ^b   Sundstrøm, Stein H ^c   von Plessen, Christian ^d   Brunsvig, Paal Fr ^e   Bremnes, Roy M ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; NSCLC; Palliative; Poor performance status; Quality of life; Representative population

Indexed keywords

CARBOPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD TRANSFUSION; CANCER PAIN; CANCER SURVIVAL; DRUG FATALITY; DYSPNEA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; KAPLAN-MEIERS ESTIMATE; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME; VINBLASTINE;

EID: 55049094920     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.003     Document Type: Article

References (32)

1. Bulzebruck H., Bopp R., Drings P., Bauer E., Krysa S., Probst G., et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70 (1992) 1102-1110
2. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 (1980) 25-32
3. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
4. Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 31 (2004) 3-7
5. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13 (1995) 1221-1230
6. Billingham L.J., and Cullen M.H. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 12 (2001) 1671-1675
7. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S., Creech R.H., Mason B.A., Joss R.A., et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4 (1986) 14-22
8. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
9. Soria J.C., Brisgand D., and Le C.T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?. Ann Oncol 12 (2001) 1667-1670
10. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92 (2001) 2639-2647
11. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
12. Burdett S., Johnson D., Stewart L., Tierney J., and Le Pechoux C. Supportive care and chemotherapy (CT) versus supportive care alone in advanced Non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs). J Thorac Oncol 2 Suppl4 (2007) S334. [Ref Type: Abstract]
13. Helbekkmo N., Sundstrom S.H., Aasebo U., Brunsvig P.F., von Plessen C., Hjelde H.H., et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97 (2007) 283-289
14. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
15. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., and Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A (1994) 635-642
16. Fayers P., and Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38 Suppl. 4 (2002) S125-S133
17. Osoba D., Rodrigues G., Myles J., Zee B., and Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
18. Loprinzi C.L., Laurie J.A., Wieand H.S., Krook J.E., Novotny P.J., Kugler J.W., et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 12 (1994) 601-607
19. Taylor A.E., Olver I.N., Sivanthan T., Chi M., and Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer 7 (1999) 332-335
20. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23 (2005) 190-196
21. Langer C., Li S., Schiller J., Rapoport B.L., and Johnson D.H. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 25 (2007) 418-423
22. Ardizzoni A., Boni L., Tiseo M., Fosella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
23. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
24. Perrone F., Di M.M., Gallo C., and Gridelli C. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 22 (2004) 5018-5020
25. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
26. Stinchcombe T.E., Choi J., Schell M.J., Mears A., Jones P.E., Nachtsheim R.V., et al. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer 51 (2006) 237-243
27. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
28. Alberola V., Camps C., Provencio M., Isla D., Rosell R., Vadell C., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
29. Kosmidis P.A., Dimopoulos M.A., Syrigos K., Nicolaides C., Aravantinos G., Boukovinas I., et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2 (2007) 135-140
30. Gridelli C., Ardizzoni A., Le C.T., Manegold C., Perrone F., Thatcher N., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15 (2004) 419-426
31. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetiyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
32. Sculier J.P., Lafitte J.J., Paesmans M., Lecomte J., Alexopoulos C.G., van Cutsem O., et al. Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30 (2007) 1186-1192